Inovio Pharmaceuticals(US:INO) Globenewswire·2026-03-09 19:53Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2]. - The lead plaintiff acts on behalf of other class members in directing the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting that many firms issuing notices may lack relevant experience [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has been ranked highly for its success in securities class action settlements [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA [4]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval, leading to overstated regulatory and commercial prospects [4]. - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [4].